title: Treatment in juvenile rheumatoid arthritis and new treatment options.
abstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of the childhood with the highest risk of disability. Active disease persists in the adulthood in a significant portion of children with juvenile rheumatoid arthritis despite many developments in the diagnosis and treatment. Therefore, initiation of efficient treatment in the early period of the disease may provide faster control of the inflammation and prevention of long-term harms. In recent years, treatment options have also increased in children with juvenile idiopathic arthritis owing to biological medications. All biological medications used in children have been produced to target the etiopathogenesis leading to disease including anti-tumor necrosis factor, anti-interleukin 1 and anti-interleukin 6 drugs. In this review, scientific data about biological medications used in the treatment of rheumatoid arthritis and new treatment options will be discussed.
authors.affiliation: Department of Pediatrics, Division of Pediatric Rheumatology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
authors.forename: Özgür
authors.initials: Ö
authors.lastname: Kasapçopur
authors.affiliation: Department of Pediatrics, Division of Pediatric Rheumatology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey.
authors.forename: Kenan
authors.initials: K
authors.lastname: Barut
keywords: Adalimumab; anakinra; anti-TNF agents; etanercept; infliximab; juvenile idiopatic arthritis; kanakunimab; pediatric rheumatology; treatment